PCN ARRS Pharmacists – A UK Primary Care Asset
Key Takeaways
- NHS England has increased the ARRS reimbursement caps for 2025/26 to align with Agenda for Change (AfC) pay uplifts.
- The total ARRS funding pot has expanded significantly, now exceeding £1.4 billion nationally to support multidisciplinary teams.
- Funding for pharmacists and technicians now includes specific provisions for higher band roles, reflecting the move toward advanced clinical practice.
- Partnering with a managed service like TMMT allows PCNs to utilize this increased funding without the operational burden of direct recruitment and supervision
Introduction
In the current UK healthcare climate, the pharmacist is no longer just a support role; they are a clinical necessity. Primary Care Networks (PCNs) rely on these medication experts to manage complex polypharmacy, conduct safety audits, and lead chronic disease clinics. The primary engine behind this workforce shift is the Additional Roles Reimbursement Scheme (ARRS). Recognizing the inflationary pressures and the need for competitive pay, NHS England has recently implemented several funding boosts to ensure that PCNs can continue to recruit and retain high-calibre pharmacy professionals.
Understanding the Figures
The latest updates to the GP contract and ARRS guidelines show a clear commitment to financial sustainability. For the 2025/26 period, NHS England confirmed a significant increase in the reimbursement caps for clinical pharmacists and pharmacy technicians.
For instance, the maximum reimbursement for a Band 7 pharmacist has risen to approximately £66,972, while Band 8a roles have seen similar adjustments to stay in line with the Agenda for Change (AfC) pay scales. This roughly 4-5% increase is designed to cover not only base salaries but also the rising costs of employer National Insurance and pension contributions.
Navigating the 2025/26 Funding Landscape
The recent updates to the NHS England Network Contract DES signal a significant shift in how Primary Care Networks (PCNs) can utilize the Additional Roles Reimbursement Scheme (ARRS). With an overall 16% uplift in ARRS funding (increasing to £26.631 per weighted patient), the financial envelope for multidisciplinary teams is larger than ever.
This expansion is designed to resolve the “GP employment paradox”, the systemic gap where a shortage of clinicians exists alongside a lack of direct practice funding to hire them.
Enhanced Reimbursement Caps for Pharmacy Roles
For the 2025/26 contract year, the maximum reimbursement amounts for core pharmacy roles have been increased to account for pay awards and operational costs:
- Clinical Pharmacists (Band 7-8a): The national reimbursement cap has risen to £66,972, a 1.7% increase from previous rates.
- Pharmacy Technicians: To better support the technical workforce, the reimbursement cap has seen a 2.2% uplift, now reaching £43,352.
These adjustments ensure that practices can offer competitive packages to attract high caliber talent without exhausting their budgets prematurely.
The Causes and Implications of the Boost
This funding injection is a direct response to two factors: the mandatory NHS pay uplifts and the ambitious goals of the NHS Long Term Workforce Plan. By increasing the caps, the government aims to prevent “pay erosion” that might otherwise see skilled pharmacists leave primary care for the private sector. The implication for PCNs is clear: there is more financial “headroom” to hire experienced, senior pharmacists who can take on advanced clinical responsibilities, such as independent prescribing and complex diagnostic tasks. This ensures that the multidisciplinary team (MDT) remains a high quality alternative to traditional GP only models.
Strategic Advantages for PCN Leadership
The primary advantage of these increased caps is the ability to build a more resilient workforce. With higher funding thresholds, PCNs can now afford to recruit Pharmacy Technicians alongside pharmacists to create a tiered pharmacy “hub.” This hub can handle everything from technical medicine reconciliations to high-level clinical reviews.
By utilizing the full breadth of the ARRS pot, which is now calculated at approximately £26.63 to £29.67 per weighted patient; networks can significantly reduce the “admin-heavy” prescribing tasks that typically drain GP time, thereby improving overall practice morale and patient access.
How The Medicines Management Team Helps You Harness This Trend
While the funding is more accessible, the challenge of implementation remains. Many PCNs struggle to find the time to manage the recruitment, induction, and ongoing clinical supervision that these roles require. This is where The Medicines Management Team (TMMT) provides a critical advantage. We enable PCNs to fully utilize their ARRS funding through a managed service model. Because our pharmacists and technicians are provided as a turnkey solution, your network benefits from the increased funding caps without having to manage the complexities of HR, training, or clinical governance internally. We ensure your ARRS budget is transformed into an immediate, high-impact clinical service.
Conclusion
The increase in ARRS funding marks a pivotal moment for UK primary care. It provides the financial freedom to build a workforce that is fit for the future, but success depends on how those funds are deployed. Rather than letting funding go unspent due to recruitment hurdles, PCNs should look toward structured partnerships that guarantee clinical results. By aligning with a managed service, you can ensure that every pound of your ARRS budget is working to unburden your GPs and provide safer, more effective care for your patients.
To see how we can help you optimize your ARRS budget, visit our Medicines Management Service page.
Frequently Asked Questions (FAQs)
For the 2025/26 period, the reimbursement cap for a clinical pharmacist (typically Band 7) has been increased to approximately £66,972, covering salary, NI, and pension. Higher caps apply for Band 8a roles if they meet advanced practice criteria.
Yes. NHS England adjusted the ARRS reimbursement caps specifically to account for the Agenda for Change (AfC) pay uplifts, ensuring that PCNs are not left with a funding gap when paying staff the mandatory new rates.
Absolutely. As long as the staff provided meet the clinical requirements of the Network Contract DES, PCNs can utilize their ARRS budget to fund managed services like TMMT. This is often more efficient than direct hiring as it includes the cost of management and supervision.
The funding is allocated based on a “weighted patient” basis. For 2025/26, this is approximately £26.63 to £29.67 per weighted patient, depending on your specific network’s demographics and NHS England’s final annual adjustments.
Unclaimed ARRS funding is generally lost to the network at the end of the financial year. This is why many PCNs are now using managed services to quickly fill vacancies and ensure their full allocation is utilized to improve patient care.
